Given that the combination of two mAbs, binding non-overlapping epitopes, could offer complementary MOAs and lead to synergistic therapeutic efficacy, Alberti's team explored the combined in vivo activity of 2G10 and 2EF-an anti-Trop2 mAb recognizing N-terminal epitopes of Trop2-ECD with proven antitumor activity across multiple tumor models 58. Here, TACSTD2 is linked to neoplasm.